Clinical and Molecular Hepatology

Erratum to ‘MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”' [Clin Mol Hepatol 2025;31:e128-e133]: Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song; Clin Mol Hepatol 2026;32(3):1472-1472.
Published online July 1, 2026; DOI: https://doi.org/10.3350/cmh.2024.1008e; Corrects: Clin Mol Hepatol 2025;31(2):e128

MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”: Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song; Clin Mol Hepatol 2025;31(2):e128-e133.
Published online December 26, 2024; DOI: https://doi.org/10.3350/cmh.2024.1008; Correction in: Clin Mol Hepatol 2026;32(3):1472

Citations

Citations to this article as recorded by

Longitudinal changes in fatty liver index, genetic susceptibility, and incident atrial fibrillation
Siyang Liu, Houde He, Hualan Chen, Hualin Duan, Ying Sun, Dan Deng, Zihao Gui, Lan Liu, Ningjian Wang, Jie Shen, Heng Wan
Clinica Chimica Acta.2026; 589: 121028. CrossRef
Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017–2020
Xin Qiu, Shuang Shen, Nizhen Jiang, Yifei Feng, Guodong Yang, Donghong Lu
BMC Gastroenterology.2025;[Epub] CrossRef
Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Seogsong Jeong, Won Kim, Sang Min Park
Clinical and Molecular Hepatology.2025; 31(2): e210. CrossRef